Allogene reported research and development expenses of $28.6 million and general and administrative expenses of $13.8 million for Q4 2025, leading to a net loss of $38.8 million for the quarter and a full-year 2025 net loss of $190.9 million. The company held $258.3 million in cash, cash equivalents and investments as of December 31, 2025, extending its funding runway into Q1 2028.

The pivotal randomized ALPHA3 trial is evaluating cemacabtagene ansegedleucel (cema-cel) as a seventh consolidation cycle in first-line treatment of large B-cell lymphoma, enrolling patients at over 60 academic and community centers. An interim futility analysis will assess minimal residual disease clearance and safety outcomes in April 2026, comparing cema-cel after fludarabine/cyclophosphamide lymphodepletion versus observation across 24 patients.

ALLO-329, a dual CD19/CD70 AlloCAR T therapy utilizing Dagger® technology for built-in lymphodepletion, is enrolling in a 3+3 dose-escalation design across multiple autoimmune indications, including systemic lupus erythematosus and scleroderma. Initial translational and clinical data—including biomarker profiles, CAR T expansion and immune reconstitution—are expected in June 2026.

ALLO-316 remains the only allogeneic CAR T asset to show clinically significant responses and durability in metastatic renal cell carcinoma, with Phase 1b enrollment complete. The company is exploring strategic partnerships to advance this program, potentially unlocking value from its solid tumor pipeline.